INTRODUCTION
============

Plasmablastic lymphoma (PBL) is a non-Hodgkin lymphoma, variant of the diffuse large B-cell lymphoma, rare, aggressive and characterized by its plasmacytic differentiation. PBL occurs in patients with some form of immunosuppression, especially the one caused by HIV (human immunodeficiency virus) infection, and 80% of the cases associated with HIV are also positive for Epstein-Barr virus (EBV).^[@r1]-[@r4]^

It affects more men, with a 4:1 ratio and mean age of 39 years. However, due to its rarity, the exact incidence remains unknown.^[@r1],[@r2],[@r4]^

The clinical presentation is of an exophytic, painless, rapidly growing and sometimes ulcerated lesion. It has predilection for the mouth, particularly the gingivae and palate. Submandibular and cervical lymphadenopathy, as well as B-cell lymphoma symptoms like fever, night sweats and weight loss can be present.^[@r1],[@r5],[@r6]^

The differential diagnosis of an expanding oral lesion includes from infectious dental processes to malignancies. Malignancies include squamous cell carcinoma, metastatic tumors and Kaposi sarcoma. Besides plasmablastic lymphoma, other types of lymphoma can also occur in the oral cavity, including diffuse large B-cell lymphoma, plasmacytomas and Burkitt lymphoma.^[@r5]^

There is no standard treatment for plasmablastic lymphoma. However, chemotherapy remains as the treatment of choice. Recently, autologous hematopoietic stem cell transplantation has been shown to be an option, increasing patient survival.^[@r1],[@r2],[@r5]^

CASE REPORT
===========

Fifty-six-year-old female Caucasian pacient, smoker, was referred for the diagnosis of a lesion on the gingiva.

When the lesion first appeared, 1 month one month before the appointement, the patient sought a dental surgeon that upon noticing intense bone loss on the right posterior maxillary region on the radiograph, suggestive of periodontal destruction, opted to remove the affected teeth and prescribe antibiotics. Since there was no improvement, the patient was referred to our clinic.

Concomitantly, the patient was under investigation of erythematous patches, spread throughout her body that appeared 11 months earlier, leading to the diagnosis of HIV infection and cutaneous rash. She did not have any other associated conditions or history of opportunistic infections.

CD4+ cell count and viral load (VL) before antiretroviral treatment was 146 cells/mm^3^ and 1,111,978 copies/ml, respectively. Fifteen days after starting treatment with lamivudine, tenofovir and efavirenz, CD4+ cells went to 189 cells/mm³ and VL to 13,504 copies/ml.

We collected a detailed history and on physical examination a painless tumor with an erythematous surface and an ulcerated area was observed on the right upper gingiva ([Figure 1](#f1){ref-type="fig"}). The radiograph showed intense, generalized periodontal bone loss. Incisional biopsy was performed, and the sample was sent to the laboratory for analysis.

Figure 1**A.** Clinical aspect of the lesion on the first visit. **B.** Clinical aspect of the lesion on the first visit

Histopathology showed a fragment of lymphoid neoplasia, represented by a layer of bulky cells, similar to immunoblasts. Intense pleomorphism and multiple mitotic figures were also observed ([Figure 2A](#f2){ref-type="fig"}). Immunohistochemistry revealed positivity to anti-plasma cell marker and immunoglobulin kappa light chain, and was negative to anti-CD3, CD20 and lambda light chain, confirming monoclonality and plasmacytic origin of the tumor. *In situ* hybridization was positive for EBV ([Figure 2B](#f2){ref-type="fig"}). The final diagnosis of PBL was made based on the histological and immunophenotypic features.

Figure 2**A.** Histopathology showing lymphoid proliferation and intense cellular pleomorphism (Hematoxylin & eosin, X40). B. hybridization confirming the presence of Epstein-Barr virus(X40)

The patient was referred to chemotherapy treatment, having had 9 cycles of EPOCH (etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin). Afterwards, she presented with complete remission of the lesion ([Figure 3](#f3){ref-type="fig"}). She then underwent autologous hematopoietic stem cell transplantation and progressed with sepsis, bronchospasm and died due to cardiorespiratory arrest 10 months after being diagnosed with PBL.

Figure 3**A** and **B.** Complete remission of the lesion after chemotherapy

DISCUSSION
==========

With the advent of HAART, the incidence of opportunistic infections as well as the morbidity and mortality associated to HIV infection decreased, a trend that could also be seen with oral lesions.^[@r7],[@r8]^ The incidence of lymphomas associated with HIV infection in general decreased 50% after HAART was made available. However, because of the small number of cases, there is not enough information to affirm that the advent of HAART altered the prevalence of PBL.^[@r7]^

The diagnosis of oral lymphomas can be challenging because there is low clinical suspicion, leading to diagnostic errors and delayed treatment.^[@r9]^ A careful assessment, knowledge about HIV infection and its oral manifestations will help correctly and promptly diagnosing malignant lesions, avoiding situations such as in our case, where the initial diagnosis was of a dental infection.

Even though the prognosis of PBL remains somber, with mean survival of 11 to 13 months, the combination of HAART with chemotherapy has yielded better survival for HIV-positive patients. Promising results have also been reported with the use of targeted therapies against EBV, such as zidovudine, ganciclovir and interleukin-2.^[@r4],[@r10]^

PBL, an AIDS defining lesion, can be the first clinical manifestation of HIV infection and physicians must be vigilant to make an accurate and early clinical diagnosis, being able to differentiate a potentially malignant lesion from other neoplastic or infectious processes in patients, regardless of their serology, increasing their chances of survival.
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